Key points are not available for this paper at this time.
Epigenetics, the study of heritable changes in gene expression that do not involve alterations to the DNA sequence, has emerged as a transformative field in biology and medicine, revealing how gene expression is modulated in response to internal and external cues. Its applications span from understanding fundamental biological processes and disease mechanisms to developing novel diagnostics and therapies, making it a cornerstone of modern biomedical research. This report explores data from the CAS Content Collection to examine recent transformative advances in epigenetic research, highlighting technological innovations that are revolutionizing our understanding of gene regulation and therapeutic applications. Environmental epigenetic research shows strong interest, demonstrating how external factors induce heritable epigenetic changes with implications for transgenerational inheritance. These findings bridge environmental exposures with health outcomes across generations, informing public health strategies and personalized medicine approaches. Disease applications span multiple pathologies, with cancer research leading epigenetic studies. Emerging applications in aging research, metabolic diseases, and autoimmune conditions demonstrate the field's expanding clinical relevance. Clinical translation has achieved significant success, with 13 FDA-approved epigenetic drugs primarily targeting hematological malignancies through HDAC inhibitors (6 drugs) and DNMT inhibitors (2 drugs). The robust clinical pipeline includes 37 ongoing trials across novel targets, with encouraging diversification beyond oncology into metabolic, neurological, and inflammatory disorders.
Iyer et al. (Wed,) studied this question.